View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
In association with Cytiva for Cell & Gene Therapy coverage
  1. News
February 8, 2022

Nanoscope concludes enrolment in Phase IIb optogenetic gene therapy trial

The company anticipates topline data in the first quarter of next year.

Nanoscope Therapeutics has concluded subject enrolment in a Phase IIb trial of its optogenetic gene therapy, MCO-010, to restore vision in patients with retinitis pigmentosa (RP). 

The company anticipates topline data from the trial in the first quarter of next year. A total of 27 subjects with severe vision loss due to advanced RP were enrolled into the trial.

The randomised, sham-controlled, double-masked, multicentre trial will analyse the safety and efficacy of the MCO-010 therapy in RP patients. 

Participants will be administered either an MCO-010 injection or a sham injection.

Nanoscope Therapeutics CEO Sulagna Bhattacharya said: “Completing enrollment for this trial is another important milestone for Nansocope and millions suffering from retinal diseases for which there are no effective treatments. 

“Positive results from this trial will bring us closer to meeting this significant unmet medical need.”

The concluded Phase I/IIa trial that enrolled 11 RP patients showed MCO-010 was well-tolerated, enhanced quality of life consistent with substantial improvement in functional vision in individuals with advanced disease.

As per this trial data, MCO-010 could be applicable for restoring vision in retinal degenerative diseases regardless of gene mutations. 

The optogenetic monotherapy is an ambient-light activatable Multi-Characteristic Opsin (MCO). 

It leverages an adeno-associated virus type 2 (AAV2) vector to offer MCO genes into retinal cells facilitating vision in natural environments. 

The treatment is given as a single eye injection for in-office delivery without requiring any other devices or interventions. 

The US Food and Drug Administration granted orphan drug designations for MCO-010 to treat RP and Stargardt disease. 

Nanoscope also commenced a Phase II trial of the therapy in Stargardt macular degeneration.

Cell & Gene Therapy Coverage on Clinical Trials Arena supported by Cytiva.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.

Free Whitepaper

Secure the cell therapy supply chain from bench to bedside

The development of cell therapies is changing healthcare, delivering new hope to thousands of patients around the world. The vein-to-vein workflow for these therapies, however, is not without challenges, many of which will increase as we scale up to treat more patients. Download this free guide from Cytiva to learn more about the challenges and risks associated with the cryogenic supply chain for cell therapies, and how supply chain disruptions can best be mitigated.
by Cytiva Thematic

By clicking the Download Free Whitepaper button, you accept the terms and conditions and acknowledge that your data will be used as described in the Cytiva Thematic privacy policy By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Clinical Trials Arena